Drug off-target effects predicted using structural analysis in the context of a metabolic network model.

Recent advances in structural bioinformatics have enabled the prediction of protein-drug off-targets based on their ligand binding sites. Concurrent developments in systems biology allow for prediction of the functional effects of system perturbations using large-scale network models. Integration of...

Full description

Bibliographic Details
Main Authors: Roger L Chang, Li Xie, Lei Xie, Philip E Bourne, Bernhard Ø Palsson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-09-01
Series:PLoS Computational Biology
Online Access:http://europepmc.org/articles/PMC2950675?pdf=render
id doaj-411025646d134aacb96038b54f586b96
record_format Article
spelling doaj-411025646d134aacb96038b54f586b962020-11-25T01:32:34ZengPublic Library of Science (PLoS)PLoS Computational Biology1553-734X1553-73582010-09-0169e100093810.1371/journal.pcbi.1000938Drug off-target effects predicted using structural analysis in the context of a metabolic network model.Roger L ChangLi XieLei XiePhilip E BourneBernhard Ø PalssonRecent advances in structural bioinformatics have enabled the prediction of protein-drug off-targets based on their ligand binding sites. Concurrent developments in systems biology allow for prediction of the functional effects of system perturbations using large-scale network models. Integration of these two capabilities provides a framework for evaluating metabolic drug response phenotypes in silico. This combined approach was applied to investigate the hypertensive side effect of the cholesteryl ester transfer protein inhibitor torcetrapib in the context of human renal function. A metabolic kidney model was generated in which to simulate drug treatment. Causal drug off-targets were predicted that have previously been observed to impact renal function in gene-deficient patients and may play a role in the adverse side effects observed in clinical trials. Genetic risk factors for drug treatment were also predicted that correspond to both characterized and unknown renal metabolic disorders as well as cryptic genetic deficiencies that are not expected to exhibit a renal disorder phenotype except under drug treatment. This study represents a novel integration of structural and systems biology and a first step towards computational systems medicine. The methodology introduced herein has important implications for drug development and personalized medicine.http://europepmc.org/articles/PMC2950675?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Roger L Chang
Li Xie
Lei Xie
Philip E Bourne
Bernhard Ø Palsson
spellingShingle Roger L Chang
Li Xie
Lei Xie
Philip E Bourne
Bernhard Ø Palsson
Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
PLoS Computational Biology
author_facet Roger L Chang
Li Xie
Lei Xie
Philip E Bourne
Bernhard Ø Palsson
author_sort Roger L Chang
title Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
title_short Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
title_full Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
title_fullStr Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
title_full_unstemmed Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
title_sort drug off-target effects predicted using structural analysis in the context of a metabolic network model.
publisher Public Library of Science (PLoS)
series PLoS Computational Biology
issn 1553-734X
1553-7358
publishDate 2010-09-01
description Recent advances in structural bioinformatics have enabled the prediction of protein-drug off-targets based on their ligand binding sites. Concurrent developments in systems biology allow for prediction of the functional effects of system perturbations using large-scale network models. Integration of these two capabilities provides a framework for evaluating metabolic drug response phenotypes in silico. This combined approach was applied to investigate the hypertensive side effect of the cholesteryl ester transfer protein inhibitor torcetrapib in the context of human renal function. A metabolic kidney model was generated in which to simulate drug treatment. Causal drug off-targets were predicted that have previously been observed to impact renal function in gene-deficient patients and may play a role in the adverse side effects observed in clinical trials. Genetic risk factors for drug treatment were also predicted that correspond to both characterized and unknown renal metabolic disorders as well as cryptic genetic deficiencies that are not expected to exhibit a renal disorder phenotype except under drug treatment. This study represents a novel integration of structural and systems biology and a first step towards computational systems medicine. The methodology introduced herein has important implications for drug development and personalized medicine.
url http://europepmc.org/articles/PMC2950675?pdf=render
work_keys_str_mv AT rogerlchang drugofftargeteffectspredictedusingstructuralanalysisinthecontextofametabolicnetworkmodel
AT lixie drugofftargeteffectspredictedusingstructuralanalysisinthecontextofametabolicnetworkmodel
AT leixie drugofftargeteffectspredictedusingstructuralanalysisinthecontextofametabolicnetworkmodel
AT philipebourne drugofftargeteffectspredictedusingstructuralanalysisinthecontextofametabolicnetworkmodel
AT bernhardøpalsson drugofftargeteffectspredictedusingstructuralanalysisinthecontextofametabolicnetworkmodel
_version_ 1725081228565020672